Bank of America's analyst, Tazeen Ahmad, has adjusted the price target for Incyte (INCY, Financial), elevating it to $87 from the previous $86. The adjustment is accompanied by a continued Buy rating on the stock. This revision comes as part of the firm's broader update of models concerning small to mid-cap biotech companies, which is ahead of the first quarter earnings preview.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for Incyte Corp (INCY, Financial) is $73.96 with a high estimate of $92.00 and a low estimate of $52.00. The average target implies an upside of 27.05% from the current price of $58.21. More detailed estimate data can be found on the Incyte Corp (INCY) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, Incyte Corp's (INCY, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Incyte Corp (INCY, Financial) in one year is $94.81, suggesting a upside of 62.88% from the current price of $58.21. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Incyte Corp (INCY) Summary page.
